Form D · Pharmaceuticals

scPharmaceuticals Inc.

Lexington, MA · CIK 0001604950

Offering snapshot reported Jan 6, 2017 · SEC filing

Reported sold
$47M
Offering amount: $47M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 22, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 6, 2017Initial$46,962,788No comparison11SEC filing
Sep 6, 2016Initial$8,183,797No comparison15SEC filing
Sep 6, 2016Initial$4,000,000No comparison3SEC filing
Feb 4, 2016Initial$3,600,000No comparison12SEC filing
Apr 7, 2014Initial$9,053,016No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-277857
From the Total Offering Amount approximately $41,000,000 was from new shares of Series B stock sold and $5,962,788 was from the conversion of debt into Series B stock.

Source: Form D, filed Jan 6, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mette Agger Director
Abraham Ceesay Executive
Dorothy Coleman Director
Abhay Gandhi Director
Troy Ignelzi Executive
Jack Khattar Director
Pieter Muntendam Director, Executive
Kush Parmar Director
Leonard Schaeffer Director
Jonathan Silverstein Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
131 Hartwell Avenue Suite 215
Lexington, MA, 02421